BioClavis has announced the planned creation of 43 new jobs with a £10.5 million investment supported by Scottish Enterprise.
Bioclavis is a new spin-out from Californian molecular profiling company Biospyder, to be based at the Clinical Innovation Zone at Glasgow’s Queen Elizabeth University Hospital, creating 43 new jobs.
BioSpyder’s investment has been supported by a £4.5m Seek & Solve research and development grant from Scottish Enterprise. It forms part of a total investment of £10.5m, which will see BioClavis adapt BioSpyder’s TempO-Seq platform technology into a novel diagnostic tool for precision medicine in a number of high value clinical indications, in close collaboration with the health service and university researchers.
Joel McComb, CEO of BioSpyder and BioClavis said: “We’re very excited to build on the success we’ve had in other molecular profiling applications and bring this novel method to bear on discovery and deployment of next generation genomic diagnostics.
“We determined Glasgow, Scotland to be the ideal location for this initiative based in large part on the support and close working relationships with Scottish Enterprise, NHS and the University.”
A major United Nations climate change summit will take place in Glasgow in 2020. The UK has won the...Read More
M Squared, one of the world’s leading photonics and quantum technology companies, has opened a new quantum research facility...Read More
Osborne+Co’s Argyle St scheme gains Glasgow city planning approval, paving the way for the Grade A 270,000 sq ft...Read More
Sign-up to our email updates for the latest investment opportunities and information in Glasgow. Fill out the form below with your email.
